# Duloxetine

## Cymbalta 30mg

| TAH Drug Code      | [**OCYM**](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OCYM)                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
|:-------------------|:-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Treatment of major depressive disorder.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| Dosing             | Major Depression: Initial dose:40-60mg/day. Maintenance dose: 60mg/day. maximum dose: 120mg/day. Generalized Anxiety Disorder: Initial dose:30mg/day. Maintenance dose: 60mg/day. maximum dose: 120mg/day. Diabetic peripheral neuropathy: 60mg/day. maximum dose: 60mg/day. Fibromyalgia: Initial dose:30mg/day. Maintenance dose: 60mg/day. maximum dose: 60mg/day."                                                                                                                                                                           |
| Hepatic Impairment | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Renal Impairment   | Dose adjustment not necessary                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                    |
| Contraindications  | Coadministration with MAOIs; uncontrolled narrow-angle glaucoma.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
| Adverse Effects    | Nausea, dry mouth, constipation, diarrhea, vomiting, decreased appetite, wt loss, fatigue, dizziness, somnolence, tremor, increased sweating, hot flushes, blurred vision, insomnia, anxiety, sexual dysfunction. Infrequently, urinary hesitation. Dermatologic: Diaphoresis (6% to 8% ) Gastrointestinal: Constipation (5% to 15% ), Decrease in appetite, Diarrhea (7% to 13% ), Nausea (14% to 30% ), Xerostomia (5% to 18% ) Neurologic: Dizziness (6% to 17% ), Insomnia (8% to 16% ), Somnolence (7% to 21% ) Other: Fatigue (2% to 15% ) |
| Pregnancy          | Human Data Suggest Risk in 3rd Trimester                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     |

